Home Casteddu.com	FAQ My Amedeo About	Flying Publisher
	The Medical Article of the Year 2008: Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007; 447:661-78. Free full-text

Ovarian Neoplasms

Free Subscription Articles published in J Clin Oncol Retrieve available abstracts of 99 articles: HTML format

Single Articles

July 2008
1. WEBERPALS JI , Clark-Knowles KV, Vanderhyden BC
   Sporadic epithelial ovarian cancer: clinical relevance of BRCA1 inhibition in the DNA damage and repair pathway.
   J Clin Oncol. 2008;26:3259-67.
   PubMed     Related articles    Abstract available
   
   
   
2. SEHOULI J , Stengel D, Oskay-Oezcelik G, Zeimet AG, et al
   Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group.
   J Clin Oncol. 2008;26:3176-82.
   PubMed     Related articles    Abstract available
   
   
   June 2008
3. WALSH CS , Ogawa S, Karahashi H, Scoles DR, et al
   ERCC5 is a novel biomarker of ovarian cancer prognosis.
   J Clin Oncol. 2008;26:2952-8.
   PubMed     Related articles    Abstract available
   
   
   
4. GLINSKY GV
   "Stemness" genomics law governs clinical behavior of human cancer: implications for decision making in disease management.
   J Clin Oncol. 2008;26:2846-53.
   PubMed     Related articles    Abstract available
   
   
   
5. FOTOPOULOU C , duBois A, Karavas AN, Trappe R, et al
   Incidence of venous thromboembolism in patients with ovarian cancer undergoing platinum/paclitaxel-containing first-line chemotherapy: an exploratory analysis by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group.
   J Clin Oncol. 2008;26:2683-9.
   PubMed     Related articles    Abstract available
   
   
   
6. LHOMME C , Joly F, Walker JL, Lissoni AA, et al
   Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer.
   J Clin Oncol. 2008;26:2674-82.
   PubMed     Related articles    Abstract available
   
   
   
7. KAYE SB
   Reversal of drug resistance in ovarian cancer: where do we go from here?
   J Clin Oncol. 2008;26:2616-8.
   PubMed     Related articles   
   
   
   
8. GORIN I , Sastre-Garau X
   Strumal carcinoid tumor of the ovary.
   J Clin Oncol. 2008;26:2780-1.
   PubMed     Related articles   
   
   
   May 2008
9. ABOU-JAWDE RM , Oberoi SS
   Is single-agent chemotherapy acceptable in platinum-sensitive relapsed ovarian cancer?
   J Clin Oncol. 2008;26:2602-3.
   PubMed     Related articles   
   
   
   April 2008
10. VACH W , Bergmann TK, Brosen K
    No evidence for taxane/platinum pharmacogenetic markers: just lack of power?
    J Clin Oncol. 2008;26:1903-4.
    PubMed     Related articles   
    
    
    
11. PRAT A , Parera M, Del Campo JM
    Prognostic role of CA-125 nadir in stage IV epithelial ovarian cancer.
    J Clin Oncol. 2008;26:1771-2.
    PubMed     Related articles   
    
    
    
12. BRANFORD RA , Pantelidis P, Ross JR
    Ethnic considerations in pharmacogenetic studies.
    J Clin Oncol. 2008;26:1766-7.
    PubMed     Related articles   
    
    
    March 2008
13. GARFIELD DH
    Multitargeting ovarian epithelial cancer: adding the old to the new.
    J Clin Oncol. 2008;26:1565-6.
    PubMed     Related articles   
    
    
    
14. KAUFF ND , Domchek SM, Friebel TM, Robson ME, et al
    Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study.
    J Clin Oncol. 2008;26:1331-7.
    PubMed     Related articles    Abstract available
    
    
    
15. BAGGERLY KA , Coombes KR, Neeley ES
    Run batch effects potentially compromise the usefulness of genomic signatures for ovarian cancer.
    J Clin Oncol. 2008;26:1186-7.
    PubMed     Related articles   
    
    
    
16. RUDIN CM , Liu W, Desai A, Karrison T, et al
    Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity.
    J Clin Oncol. 2008;26:1119-27.
    PubMed     Related articles    Abstract available
    
    
    February 2008
17. FERRANDINA G , Ludovisi M, Lorusso D, Pignata S, et al
    Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer.
    J Clin Oncol. 2008;26:890-6.
    PubMed     Related articles    Abstract available
    
    
    January 2008
18. LANDEN CN JR , Birrer MJ, Sood AK
    Early Events in the Pathogenesis of Epithelial Ovarian Cancer.
    J Clin Oncol. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
19. GARCIA AA , Hirte H, Fleming G, Yang D, et al
    Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia.
    J Clin Oncol. 2008;26:76-82.
    PubMed     Related articles    Abstract available
    
    
    
20. MALACRIDA S , Agata S, Callegaro M, Casella C, et al
    BRCA1 p.Val1688del is a deleterious mutation that recurs in breast and ovarian cancer families from Northeast Italy.
    J Clin Oncol. 2008;26:26-31.
    PubMed     Related articles    Abstract available
    
    
    
21. CHETRIT A , Hirsh-Yechezkel G, Ben-David Y, Lubin F, et al
    Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer.
    J Clin Oncol. 2008;26:20-5.
    PubMed     Related articles    Abstract available
    
    
    
22. KAUFF ND
    Is It time to stratify for BRCA mutation status in therapeutic trials in ovarian cancer?
    J Clin Oncol. 2008;26:9-10.
    PubMed     Related articles   
    
    
    
23. DOMCHEK S , Weber BL
    Genetic variants of uncertain significance: flies in the ointment.
    J Clin Oncol. 2008;26:16-7.
    PubMed     Related articles   
    
    
    December 2007
24. LEE HC , Chu CY, Hsiao CH
    Carcinoma erysipeloides from ovarian clear-cell carcinoma.
    J Clin Oncol. 2007;25:5828-30.
    PubMed     Related articles   
    
    
    
25. CLARK TG , Stewart M, Rye T, Smyth JF, et al
    Validation of a new prognostic index for advanced epithelial ovarian cancer: results from its application to a UK-based cohort.
    J Clin Oncol. 2007;25:5669-70.
    PubMed     Related articles   
    
    
    
26. MILAM RA , Milam MR, Iyer RB
    Detection of early-stage ovarian cancer by FDG-PET-CT in a patient with BRCA2-positive breast cancer.
    J Clin Oncol. 2007;25:5657-8.
    PubMed     Related articles   
    
    
    November 2007
27. CANNISTRA SA , Matulonis UA, Penson RT, Hambleton J, et al
    Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.
    J Clin Oncol. 2007;25:5180-6.
    PubMed     Related articles    Abstract available
    
    
    
28. SMITH S , Su D, Rigault de la Longrais IA, Schwartz P, et al
    ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy.
    J Clin Oncol. 2007;25:5172-9.
    PubMed     Related articles    Abstract available
    
    
    
29. BURGER RA , Sill MW, Monk BJ, Greer BE, et al
    Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study.
    J Clin Oncol. 2007;25:5165-71.
    PubMed     Related articles    Abstract available
    
    
    
30. KAYE SB
    Bevacizumab for the treatment of epithelial ovarian cancer: will this be its finest hour?
    J Clin Oncol. 2007;25:5150-2.
    PubMed     Related articles   
    
    
    
31. WINTER WE 3RD , Maxwell GL, Tian C, Sundborg MJ, et al
    Tumor Residual After Surgical Cytoreduction in Prediction of Clinical Outcome in Stage IV Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study.
    J Clin Oncol. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
32. WAGNER LI , Wenzel L, Shaw E, Cella D, et al
    Patient-reported outcomes in phase II cancer clinical trials: lessons learned and future directions.
    J Clin Oncol. 2007;25:5058-62.
    PubMed     Related articles    Abstract available
    
    
    
33. DIEZ O , Gutierrez-Enriquez S, Ramon y Cajal T, Alonso C, et al
    Caution should be used when interpreting alterations affecting the exon 3 of the BRCA2 gene in breast/ovarian cancer families.
    J Clin Oncol. 2007;25:5035-6.
    PubMed     Related articles   
    
    
    
34. CHI DS , Ramirez PT, Teitcher JB, Mironov S, et al
    Prospective study of the correlation between postoperative computed tomography scan and primary surgeon assessment in patients with advanced ovarian, tubal, and peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residual di
    J Clin Oncol. 2007;25:4946-51.
    PubMed     Related articles    Abstract available
    
    
    October 2007
35. MARSH S , Paul J, King CR, Gifford G, et al
    Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer.
    J Clin Oncol. 2007;25:4528-35.
    PubMed     Related articles    Abstract available
    
    
    
36. VOGEL KJ , Atchley DP, Erlichman J, Broglio KR, et al
    BRCA1 and BRCA2 genetic testing in Hispanic patients: mutation prevalence and evaluation of the BRCAPRO risk assessment model.
    J Clin Oncol. 2007;25:4635-41.
    PubMed     Related articles    Abstract available
    
    
    
37. SPRIGGS DR , Brady MF, Vaccarello L, Clarke-Pearson DL, et al
    Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study.
    J Clin Oncol. 2007;25:4466-71.
    PubMed     Related articles    Abstract available
    
    
    
38. HSU DS , Balakumaran BS, Acharya CR, Vlahovic V, et al
    Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer.
    J Clin Oncol. 2007;25:4350-7.
    PubMed     Related articles    Abstract available
    
    
    September 2007
39. TIMMERMAN D , Van Calster B, Jurkovic D, Valentin L, et al
    Inclusion of CA-125 does not improve mathematical models developed to distinguish between benign and malignant adnexal tumors.
    J Clin Oncol. 2007;25:4194-200.
    PubMed     Related articles    Abstract available
    
    
    
40. MOORE RG , Bast RC Jr
    How do you distinguish a malignant pelvic mass from a benign pelvic mass? Imaging, biomarkers, or none of the above.
    J Clin Oncol. 2007;25:4159-61.
    PubMed     Related articles   
    
    
    
41. CALLAHAN MJ , Crum CP, Medeiros F, Kindelberger DW, et al
    Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction.
    J Clin Oncol. 2007;25:3985-90.
    PubMed     Related articles    Abstract available
    
    
    August 2007
42. MARKMAN M
    Concept of Optimal Surgical Cytoreduction in Advanced Ovarian Cancer: A Brief Critique and a Call for Action.
    J Clin Oncol. 2007;.
    PubMed     Related articles   
    
    
    
43. WINTER WE 3RD , Maxwell GL, Tian C, Carlson JW, et al
    Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study.
    J Clin Oncol. 2007;25:3621-7.
    PubMed     Related articles    Abstract available
    
    
    
44. LIU PY , Alberts DS, Monk BJ, Brady M, et al
    An early signal of CA-125 progression for ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy.
    J Clin Oncol. 2007;25:3615-20.
    PubMed     Related articles    Abstract available
    
    
    
45. TUMMALA MK , McGuire WP
    Ovarian cancer, CA-125 addiction, and informed confusion: much ado about less.
    J Clin Oncol. 2007;25:3570-1.
    PubMed     Related articles   
    
    
    
46. MOBUS V , Wandt H, Frickhofen N, Bengala C, et al
    High-Dose Sequential Chemotherapy With Peripheral Blood Stem Cell Support Compared With Standard Dose Chemotherapy for First-Line Treatment of Advanced Ovarian Cancer: Results of a Phase III Intergroup Trial of the AGO-Ovar/AIO and EBMT.
    J Clin Oncol. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
47. OZOLS RF
    Ovarian Cancer: Is Dose Intensity Dead?
    J Clin Oncol. 2007;.
    PubMed     Related articles   
    
    
    
48. MARKMAN M
    Does ovarian cancer treatment and survival differ by the specialty providing chemotherapy?
    J Clin Oncol. 2007;25:3554.
    PubMed     Related articles   
    
    
    
49. MCGUIRE WP
    Ovarian cancer and the battle of the specialists.
    J Clin Oncol. 2007;25:3554-5.
    PubMed     Related articles   
    
    
    
50. HOFFMAN MA , Iqbal U
    Type of oncology specialist and treatment-related outcomes in ovarian cancer.
    J Clin Oncol. 2007;25:3553.
    PubMed     Related articles   
    
    
    
51. BERCHUCK A
    Chemotherapy administration for ovarian cancer by gynecologic oncologists and medical oncologists.
    J Clin Oncol. 2007;25:3552.
    PubMed     Related articles   
    
    
    
52. BLANK SV , Curtin JP
    More than a name.
    J Clin Oncol. 2007;25:3551.
    PubMed     Related articles   
    
    
    
53. TERAMUKAI S , Ochiai K, Tada H, Fukushima M, et al
    PIEPOC: A New Prognostic Index for Advanced Epithelial Ovarian Cancer Japan Multinational Trial Organization OC01-01.
    J Clin Oncol. 2007;25:3302-6.
    PubMed     Related articles    Abstract available
    
    
    
54. DE BOCK GH , Mourits MJ, Oosterwijk JC
    One risk fits all?
    J Clin Oncol. 2007;25:3383-4.
    PubMed     Related articles   
    
    
    July 2007
55. TROPE C , Kaern J
    Adjuvant chemotherapy for early-stage ovarian cancer: review of the literature.
    J Clin Oncol. 2007;25:2909-20.
    PubMed     Related articles    Abstract available
    
    
    
56. BURGER RA
    Experience with bevacizumab in the management of epithelial ovarian cancer.
    J Clin Oncol. 2007;25:2902-8.
    PubMed     Related articles    Abstract available
    
    
    
57. MARTIN L , Schilder R
    Novel approaches in advancing the treatment of epithelial ovarian cancer: the role of angiogenesis inhibition.
    J Clin Oncol. 2007;25:2894-901.
    PubMed     Related articles    Abstract available
    
    
    
58. SABBATINI P , Odunsi K
    Immunologic approaches to ovarian cancer treatment.
    J Clin Oncol. 2007;25:2884-93.
    PubMed     Related articles    Abstract available
    
    
    
59. RAO G , Crispens M, Rothenberg ML
    Intraperitoneal chemotherapy for ovarian cancer: overview and perspective.
    J Clin Oncol. 2007;25:2867-72.
    PubMed     Related articles    Abstract available
    
    
    
60. COLOMBO N , Parma G, Zanagnolo V, Insinga A, et al
    Management of ovarian stromal cell tumors.
    J Clin Oncol. 2007;25:2944-51.
    PubMed     Related articles    Abstract available
    
    
    
61. GERSHENSON DM
    Management of ovarian germ cell tumors.
    J Clin Oncol. 2007;25:2938-43.
    PubMed     Related articles    Abstract available
    
    
    
62. CADRON I , Leunen K, Van Gorp T, Amant F, et al
    Management of borderline ovarian neoplasms.
    J Clin Oncol. 2007;25:2928-37.
    PubMed     Related articles    Abstract available
    
    
    
63. KAUFF ND , Barakat RR
    Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2.
    J Clin Oncol. 2007;25:2921-7.
    PubMed     Related articles    Abstract available
    
    
    
64. FADER AN , Rose PG
    Role of surgery in ovarian carcinoma.
    J Clin Oncol. 2007;25:2873-83.
    PubMed     Related articles    Abstract available
    
    
    
65. MUTCH DG , Orlando M, Goss T, Teneriello MG, et al
    Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer.
    J Clin Oncol. 2007;25:2811-8.
    PubMed     Related articles    Abstract available
    
    
    
66. GERSHENSON DM , Miller AM, Champion VL, Monahan PO, et al
    Reproductive and sexual function after platinum-based chemotherapy in long-term ovarian germ cell tumor survivors: a Gynecologic Oncology Group Study.
    J Clin Oncol. 2007;25:2792-7.
    PubMed     Related articles    Abstract available
    
    
    June 2007
67. CAPALBO C , Buffone A, Vestri A, Ricevuto E, et al
    Does the search for large genomic rearrangements impact BRCAPRO carrier prediction?
    J Clin Oncol. 2007;25:2632-4.
    PubMed     Related articles   
    
    
    
68. BIRRER MJ , Johnson ME, Hao K, Wong KK, et al
    Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas.
    J Clin Oncol. 2007;25:2281-7.
    PubMed     Related articles    Abstract available
    
    
    May 2007
69. LIAVAAG AH , Dorum A, Fossa SD, Trope C, et al
    Controlled study of fatigue, quality of life, and somatic and mental morbidity in epithelial ovarian cancer survivors: how lucky are the lucky ones?
    J Clin Oncol. 2007;25:2049-56.
    PubMed     Related articles    Abstract available
    
    
    
70. ZIGHELBOIM I , Goodfellow PJ, Gao F, Gibb RK, et al
    Microsatellite instability and epigenetic inactivation of MLH1 and outcome of patients with endometrial carcinomas of the endometrioid type.
    J Clin Oncol. 2007;25:2042-8.
    PubMed     Related articles    Abstract available
    
    
    
71. MACHADO PM , Brandao RD, Cavaco BM, Eugenio J, et al
    Screening for a BRCA2 rearrangement in high-risk breast/ovarian cancer families: evidence for a founder effect and analysis of the associated phenotypes.
    J Clin Oncol. 2007;25:2027-34.
    PubMed     Related articles    Abstract available
    
    
    April 2007
72. HERMSEN BB , von Mensdorff-Pouilly S, Berkhof J, van Diest PJ, et al
    Serum CA-125 in relation to adnexal dysplasia and cancer in women at hereditary high risk of ovarian cancer.
    J Clin Oncol. 2007;25:1383-9.
    PubMed     Related articles    Abstract available
    
    
    
73. CHEN S , Parmigiani G
    Meta-analysis of BRCA1 and BRCA2 penetrance.
    J Clin Oncol. 2007;25:1329-33.
    PubMed     Related articles    Abstract available
    
    
    
74. KARLAN BY , McIntosh M
    The quest for ovarian cancer's Holy Grail: can CA-125 still be the chalice of early detection?
    J Clin Oncol. 2007;25:1303-4.
    PubMed     Related articles   
    
    
    
75. SILBER JH , Rosenbaum PR, Polsky D, Ross RN, et al
    Does ovarian cancer treatment and survival differ by the specialty providing chemotherapy?
    J Clin Oncol. 2007;25:1169-75.
    PubMed     Related articles    Abstract available
    
    
    
76. CANNISTRA SA
    Gynecologic oncology or medical oncology: what's in a name?
    J Clin Oncol. 2007;25:1157-9.
    PubMed     Related articles   
    
    
    March 2007
77. BUCKANOVICH RJ , Sasaroli D, O'brien-Jenkins A, Botbyl J, et al
    Tumor vascular proteins as biomarkers in ovarian cancer.
    J Clin Oncol. 2007;25:852-61.
    PubMed     Related articles    Abstract available
    
    
    February 2007
78. DRESSMAN HK , Berchuck A, Chan G, Zhai J, et al
    An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer.
    J Clin Oncol. 2007;25:517-25.
    PubMed     Related articles    Abstract available
    
    
    
79. EINHORN LH , Brames MJ, Juliar B, Williams SD, et al
    Phase II study of paclitaxel plus gemcitabine salvage chemotherapy for germ cell tumors after progression following high-dose chemotherapy with tandem transplant.
    J Clin Oncol. 2007;25:513-6.
    PubMed     Related articles    Abstract available
    
    
    
80. WENZEL LB , Huang HQ, Armstrong DK, Walker JL, et al
    Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study.
    J Clin Oncol. 2007;25:437-43.
    PubMed     Related articles    Abstract available
    
    
    
81. AXTELL AE , Lee MH, Bristow RE, Dowdy SC, et al
    Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer.
    J Clin Oncol. 2007;25:384-9.
    PubMed     Related articles    Abstract available
    
    
    January 2007
82. MADALINSKA JB , van Beurden M, Bleiker EM, Valdimarsdottir HB, et al
    Predictors of prophylactic bilateral salpingo-oophorectomy compared with gynecologic screening use in BRCA1/2 mutation carriers.
    J Clin Oncol. 2007;25:301-7.
    PubMed     Related articles    Abstract available
    
    
    
83. GRUSENMEYER PA , Wong YN
    Interpreting the economic literature in oncology.
    J Clin Oncol. 2007;25:196-202.
    PubMed     Related articles    Abstract available
    
    
    October 2006
84. MURUGAESU N , Schmid P, Dancey G, Agarwal R, et al
    Malignant ovarian germ cell tumors: identification of novel prognostic markers and long-term outcome after multimodality treatment.
    J Clin Oncol. 2006;24:4862-6.
    PubMed     Related articles    Abstract available
    
    
    
85. HECHT JL , Mutter GL
    Molecular and pathologic aspects of endometrial carcinogenesis.
    J Clin Oncol. 2006;24:4783-91.
    PubMed     Related articles    Abstract available
    
    
    
86. ARMSTRONG DK , Brady MF
    Intraperitoneal therapy for ovarian cancer: a treatment ready for prime time.
    J Clin Oncol. 2006;24:4531-3.
    PubMed     Related articles   
    
    
    
87. GORE M , du Bois A, Vergote I
    Intraperitoneal chemotherapy in ovarian cancer remains experimental.
    J Clin Oncol. 2006;24:4528-30.
    PubMed     Related articles   
    
    
    September 2006
88. PFISTERER J , Plante M, Vergote I, du Bois A, et al
    Gemcitabine Plus Carboplatin Compared With Carboplatin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer: An Intergroup Trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.
    J Clin Oncol. 2006;.
    PubMed     Related articles    Abstract available
    
    
    August 2006
89. KNUTSON KL , Krco CJ, Erskine CL, Goodman K, et al
    T-Cell Immunity to the Folate Receptor Alpha Is Prevalent in Women With Breast or Ovarian Cancer.
    J Clin Oncol. 2006;.
    PubMed     Related articles    Abstract available
    
    
    
90. TANNER B , Hasenclever D, Stern K, Schormann W, et al
    ErbB-3 Predicts Survival in Ovarian Cancer.
    J Clin Oncol. 2006;.
    PubMed     Related articles    Abstract available
    
    
    
91. GORDON MS , Matei D, Aghajanian C, Matulonis UA, et al
    Clinical Activity of Pertuzumab (rhuMAb 2C4), a HER Dimerization Inhibitor, in Advanced Ovarian Cancer: Potential Predictive Relationship With Tumor HER2 Activation Status.
    J Clin Oncol. 2006;.
    PubMed     Related articles    Abstract available
    
    
    
92. MADALINSKA JB , van Beurden M, Bleiker EM, Valdimarsdottir HB, et al
    The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy.
    J Clin Oncol. 2006;24:3576-82.
    PubMed     Related articles    Abstract available
    
    
    
93. SCHOVER LR
    Is the fault in our steroids or in our selves?
    J Clin Oncol. 2006;24:3519-21.
    PubMed     Related articles   
    
    
    July 2006
94. MARKMAN M
    Normal CA-125 and the risk of progression in ovarian cancer.
    J Clin Oncol. 2006;24:3310.
    PubMed     Related articles   
    
    
    
95. ANTONIOU AC , Pharoah PD, Easton DF, Evans DG, et al
    BRCA1 and BRCA2 cancer risks.
    J Clin Oncol. 2006;24:3312-3.
    PubMed     Related articles   
    
    
    
96. EVANS DG , Lalloo F, Eccles D
    Optimal selection of individuals for BRCA mutation testing.
    J Clin Oncol. 2006;24:3311.
    PubMed     Related articles   
    
    
    May 2006
97. ALETTI GD , Cliby WA
    Importance of Surgical Aggressiveness in Advanced Ovarian Cancer.
    J Clin Oncol. 2006;24:2397.
    PubMed     Related articles   
    
    
    
98. CHI DS , Barakat RR
    Aggressive Surgery and Ovarian Cancer.
    J Clin Oncol. 2006;24:2395-2396.
    PubMed     Related articles   
    
    
    March 2006
99. MARKMAN M , Liu PY, Rothenberg ML, Monk BJ, et al
    Pretreatment CA-125 and risk of relapse in advanced ovarian cancer.
    J Clin Oncol. 2006;24:1454-8.
    PubMed     Related articles    Abstract available
    
    

Thank you for your interest in scientific medicine.

Amedeo is a Bernd Sebastian Kamps website.    Design: